Dracoflavan A



Compound IDCDAMM01528
Common nameDracoflavan A
IUPAC name[2-[2,2-bis(7-hydroxy-5-methoxy-2-phenyl-3,4-dihydro-2H-chromen-8-yl)ethyl]-5-hydroxy-3-methoxy-4-methylphenyl] benzoate
Molecular formulaC49H46O10

Experimental data

Retention time5.62
Adduct[M+H]+
Actual mz795.317
Theoretical mz795.316
Error0.41
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.1247

Identifiers and class information

Inchi keyVOQIJACLUQIMIE-KYOVUXSFNA-N
SmilesO=C(OC1=CC(O)=C(C(OC)=C1CC(C2=C(O)C=C(OC)C3=C2OC(C=4C=CC=CC4)CC3)C5=C(O)C=C(OC)C6=C5OC(C=7C=CC=CC7)CC6)C)C=8C=CC=CC8
SuperclassPhenylpropanoids and polyketides
ClassDepsides and depsidones

Pharmacokinetic properties

Number of descriptor values(#stars)11
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)12
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)794.896
Computed dipole moment(dipole)5.104
Total solvent accessible surface area (SASA)1018.26
Hydrophobic component of SASA (FOSA)444.649
Hydrophilic component of SASA (FISA)100.587
Pie component of the SASA (PISA)473.028
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2188.93
Number of hydrogen bond donors (donorHB)3
Number of hydrogen bond acceptors (accptHB)8.5
Free energy of solvation of dipole (dip^2/V)0.011903
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0144584
Globularity descriptor (glob)0.800682
Predicted polarizability in cubic angstroms (QPpolrz)78.259
Predicted hexadecane/gas partition coefficient (QPlogPC16)22.654
Predicted octanol/gas partition coefficient (QPlogPoct)36.034
Predicted water/gas partition coefficient (QPlogPw)16.191
Predicted octanol/water partition coefficient (QPlogPo/w)9.036
Predicted aqueous solubility (QPlogS)-9.35
Conformation-independent predicted aqueous solubility (CIQPlogS)-14.096
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-7.013
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1101.64
Predicted brain/blood partition coefficient (QPlogBB)-1.206
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)549.273
Predicted skin permeability, log Kp (QPlogKp)-0.555
PM3 calculated ionization potential (IP(ev))8.502
PM3 calculated electron affinity (EA(eV))0.289
Number of likely metabolic reactions (#metab)15
Prediction of binding to human serum albumin (QPlogKhsa)2.262
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)100
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)114.531
Number of nitrogen and oxygen atoms (#NandO)10
Number of violations of Lipinski’s rule of five (RuleOfFive)2
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P0DMS8ADORA3Adenosine A3 receptorT36059SwissTargetPrediction
P14555PLA2G2APhospholipase A2 group IIAT19160SwissTargetPrediction
P22748CA4Carbonic anhydrase IVT53378SwissTargetPrediction
P11926ODC1Ornithine decarboxylaseT60366SEA
Q92731ESR2Estrogen receptor betaT80896SwissTargetPrediction
P11511CYP19A1Cytochrome P450 19A1T13260SwissTargetPrediction
P06746POLBDNA polymerase beta (by homology)T06958SwissTargetPrediction
P08253MMP2Matrix metalloproteinase 2T68251SwissTargetPrediction
P22894MMP8Matrix metalloproteinase 8T08856SwissTargetPrediction
P14780MMP9Matrix metalloproteinase 9T54156SwissTargetPrediction
P03372ESR1Estrogen receptor alphaT02506SwissTargetPrediction
P03956MMP1Matrix metalloproteinase 1T52450SwissTargetPrediction
Q14534SQLESqualene monooxygenase (by homology)T93344SwissTargetPrediction
P05121SERPINE1Plasminogen activator inhibitor-1T15556SwissTargetPrediction
P08183ABCB1P-glycoprotein 1T25258SEA
Q15118PDK1Pyruvate dehydrogenase kinase isoform 1T20891SwissTargetPrediction
P08238HSP90AB1Heat shock protein HSP 90-betaT96623SwissTargetPrediction
P15692VEGFAVascular endothelial growth factor AT20761SwissTargetPrediction
P25101EDNRAEndothelin receptor ET-AT23499SwissTargetPrediction
P49763PGFPlacenta growth factorT70792SwissTargetPrediction
P20839IMPDH1Inosine-5'-monophosphate dehydrogenase 1T40111SEA
P32418SLC8A1Sodium/calcium exchanger 1T07775SEA
Q16678CYP1B1Cytochrome P450 1B1T92521SwissTargetPrediction
Q16665HIF1AHypoxia-inducible factor 1 alphaT55610SwissTargetPrediction
P16152CBR1Carbonyl reductase [NADPH] 1T70518SwissTargetPrediction
P41235HNF4AHepatocyte nuclear factor 4-alphaT15514SwissTargetPrediction
O43826SLC37A4Glucose-6-phosphate translocaseT47306SEA
Q8N183NDUFAF2HUMAN NADH:ubiquinone oxidoreductase complex assembly factor 2T01453SEA
Q9P0J0NDUFA13Mitochondrial complex IT82391SEA
Q9Y6M9NDUFB9HUMAN NADH:ubiquinone oxidoreductase subunit B9T01465SEA
Q8N183NDUFAF2HUMAN NADH:ubiquinone oxidoreductase complex assembly factor 2T01453SEA
P03897MT-ND3NADH dehydrogenaseT77195SEA
H3BPQ1TCF4Transcription factor 7-like 2T54646SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T36059DI0351Psoriasis[ICD-11: EA90]P0DMS8ADORA3
T36059DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P0DMS8ADORA3
T19160DI0062Breast cancer[ICD-11: 2C60-2C6Y]P14555PLA2G2A
T53378DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P22748CA4
T53378DI0166Glaucoma[ICD-11: 9C61]P22748CA4
T53378DI0372Seborrhoeic dermatitis[ICD-11: EA81]P22748CA4
T60366DI0020African trypanosomiasis[ICD-11: 1F51]P11926ODC1
T80896DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q92731ESR2
T80896DI0108Cushing syndrome[ICD-11: 5A70]Q92731ESR2
T80896DI0254Menopausal disorder[ICD-11: GA30]Q92731ESR2
T80896DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q92731ESR2
T13260DI0062Breast cancer[ICD-11: 2C60-2C6Y]P11511CYP19A1
T13260DI0108Cushing syndrome[ICD-11: 5A70]P11511CYP19A1
T06958DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P06746POLB
T68251DI0238Lung cancer[ICD-11: 2C25]P08253MMP2
T08856DI0366Rheumatoid arthritis[ICD-11: FA20]P22894MMP8
T54156DI0219Ischaemic/haemorrhagic stroke[ICD-11: 8B20]P14780MMP9
T54156DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P14780MMP9
T54156DI0395Stomach cancer[ICD-11: 2B72]P14780MMP9
T54156DI0419Ulcerative colitis[ICD-11: DD71]P14780MMP9
T02506DI0106COVID-19[ICD-11: 1D6Y]P03372ESR1
T52450DI0238Lung cancer[ICD-11: 2C25]P03956MMP1
T93344DI0118Dermatophytosis[ICD-11: 1F28]Q14534SQLE
T93344DI0385Skin fungal infection disorder[ICD-11: EA60]Q14534SQLE
T15556DI0037Asthma[ICD-11: CA23]P05121SERPINE1
T15556DI0405Thrombosis[ICD-11: DB61-GB90]P05121SERPINE1
T25258DI0238Lung cancer[ICD-11: 2C25]P08183ABCB1
T20891DI0241Lymphoma[ICD-11: 2A80-2A86]Q15118PDK1
T96623DI0062Breast cancer[ICD-11: 2C60-2C6Y]P08238HSP90AB1
T96623DI0238Lung cancer[ICD-11: 2C25]P08238HSP90AB1
T96623DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P08238HSP90AB1
T96623DI0249Mature B-cell leukaemia[ICD-11: 2A82]P08238HSP90AB1
T96623DI0286Myeloproliferative neoplasm[ICD-11: 2A20]P08238HSP90AB1
T96623DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P08238HSP90AB1
T96623DI0395Stomach cancer[ICD-11: 2B72]P08238HSP90AB1
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T23499DI0070Cardiovascular disease[ICD-11: BA00-BE2Z]P25101EDNRA
T23499DI0356Pulmonary hypertension[ICD-11: BB01]P25101EDNRA
T23499DI0425Urinary system clinical symptom[ICD-11: MF8Y]P25101EDNRA
T70792DI0095Colorectal cancer[ICD-11: 2B91]P49763PGF
T40111DI0062Breast cancer[ICD-11: 2C60-2C6Y]P20839IMPDH1
T40111DI0179Hepatitis virus infection[ICD-11: 1E50-1E51]P20839IMPDH1
T40111DI0250Mature B-cell lymphoma[ICD-11: 2A85]P20839IMPDH1
T40111DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P20839IMPDH1
T40111DI0413Transplant rejection[ICD-11: NE84]P20839IMPDH1
T55610DI0241Lymphoma[ICD-11: 2A80-2A86]Q16665HIF1A
T55610DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16665HIF1A
T70518DI0037Asthma[ICD-11: CA23]P16152CBR1
T82391DI0069Cardiomyopathy[ICD-11: BC43]Q9P0J0NDUFA13
T77195DI0331Parkinsonism[ICD-11: 8A00]P03897MT-ND3

Copyright © 2025